Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation

Journal of Neuro-Oncology

Volumn 78, Issue 3, 2006, Pages 295-302

  Levin, Victor A ^a   Phuphanich, Surasak ^b   Yung, W K Alfred ^a   Forsyth, Peter A ^c   Del Maestro, Rolando ^d   Perry, James R ^e   Fuller, Gregory N ^a   Baillet, Mark ^f,g  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TOM BAKER CANCER CENTRE   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^f The Marimastat Glioblastoma Study Group   (United Kingdom)

^g Pharmaceutical Services Ltd   (Poland)

Author keywords

Invasion; Marimastat; Matrix metalloprotease; Radiotherapy

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; HYDROXYUREA; IBUPROFEN; MARIMASTAT; MATRIX METALLOPROTEINASE; PARACETAMOL; PLACEBO;

ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GLIOBLASTOMA; GLIOMA; GLIOSARCOMA; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MYALGIA; OVERALL SURVIVAL; PARALLEL DESIGN; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; AGED; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; GLIOBLASTOMA; GLIOSARCOMA; HUMANS; HYDROXAMIC ACIDS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; MUSCULOSKELETAL DISEASES; QUALITY OF LIFE; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 33745793404     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-005-9098-5     Document Type: Article

References (28)

1. Levin VA, Uhm JH, Jaeckle KA, et al, Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N′-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme Clin Cancer Res 6:3878-3884, 2000
2. Levin VA, Leibel SA, Gutin PH, Neoplasms of the central nervous system in DeVita VTJ, Hellman S, Rosenberg SA, (eds): Cancer: Principles and Practice of Oncology ed 6 Lippincott-Raven Philadelphia 2001, pp 2100-2160
3. Rao JS, Yamamoto M, Mohaman S, et al., Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas Clin Exp Metastasis 14: 12-18, 1996
4. Sawaya RE, Yamamoto M, Gokaslan ZL, et al, Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo Clin Exp Metastasis 14:35-42, 1996
5. Rao JS, Molecular mechanisms of glioma invasiveness: The role of proteases Nat Rev Cancer 3:489-501, 2003
6. Zucker S, Cao J, Chen WT, Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment Oncogene 19:6642-6650, 2000
7. Brown PD, Giavazzi R, Matrix metalloproteinase inhibition: A review of anti-tumour activity Ann Oncol 6:967-974, 1995
8. Nemunaitis J, Poole C, Primrose J, et al, Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of a biologically active and tolerable dose for longer-term studies Clin Cancer Res 4:1101-1109, 1998
9. Burger PC, Vogel FS, Green SB, et al, Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications Cancer 56:1106-1111, 1985
10. Burger PC, Scheithauer BW, Vogel FS, Surgical Pathology of the Nervous System and its Coverings 3rd edn Churchill Livingstone New York 1991
11. Weitzner MA, Meyers CA, Byrne K, Psychosocial functioning and quality of life in patients with primary brain tumors J Neurosurg 84:29-34, 1996
12. Weitzner MA, Meyers CA, Gelke CK, et al, The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors Cancer 75:1151-1161, 1995
13. Macdonald DR, Cascino TL, Schold SC, Jr., et al, Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8:1277-1280, 1990
14. Levin VA, Crafts DC, Norman DM, et al, Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors J Neurosurg 47:329-335, 1977
15. Taves DR, Minimization: A new method of assigning patients to treatment and control groups Clin Pharmacol Ther 15:443-453, 1974
16. Leibel SA, Scott CB, Loeffler JS, Contemporary approaches to the treatment of malignant gliomas with radiation therapy Semin Oncol 21:198-219, 1994
17. Brown PD, Matrix metalloproteinase inhibitors: A novel class of anticancer agents Adv Enzyme Regul 35:293-301, 1995
18. Groves MD, Puduvalli VK, Hess KR, et al, Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme J Clin Oncol 20:1383-1388, 2002
19. Yung WK, Albright RE, Olson J, et al, A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse Br J Cancer 83:588-593, 2000
20. King J, Zhao J, Clingan P, et al, Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: Significant survival advantage in patients with musculoskeletal side-effects Anticancer Res 23:639-645, 2003
21. Overall CM, Lopez-Otin C, Strategies for MMP inhibition in cancer: innovations for the post-trial era Nat Rev Cancer 2:657-672, 2002
22. Coussens LM, Fingleton B, Matrisian LM, Matrix metalloproteinase inhibitors and cancer: Trials and tribulations Science 295:2387-2392, 2002
23. Patterson BC, Sang QA, Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9) J Biol Chem 272:28823-28825, 1997
24. O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, et al, Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance J Biol Chem 274:29568-29571, 1999
25. Vazquez F, Hastings G, Ortega MA, et al, METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity J Biol Chem 274:23349-23357, 1999
26. Toth M, Bernardo MM, Gervasi DC, et al, Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane type 1)-MMP-dependent activation of pro-MMP-2 J Biol Chem 275:41415-41423, 2000
27. Osoba D, Brada M, Yung WKA, et al, Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme J Clin Oncol 18:1481-1491, 2000
28. Groves ES, Puduvalli V, Conrad CA, et al.: Temozolomide plus the matrix metalloproteinase inhibitor, marimastat, for recurrent anaplastic gliomas. J Clin Oncol submitted, 2006